Royalty Pharma plc Class A Ordinary Shares (RPRX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 100
- Market Cap
- $26.2B
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
SentiSense also tracks daily options readings for Royalty Pharma plc Class A Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Royalty Pharma plc Class A Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.